Latest news with #AmpersandCapitalPartners
Yahoo
03-07-2025
- Business
- Yahoo
VIVEbiotech Appoints Patricio Massera as President
Veteran CDMO executive to guide next phase of global expansion and operational excellence for lentiviral vector manufacturer. VIVEbiotech Patricio Massera San Sebastián, Gipuzkoa, Spain, July 03, 2025 (GLOBE NEWSWIRE) -- VIVEbiotech, a leading Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral vector (LVV) development and manufacturing for in vivo and ex vivo gene and cell therapies, today announced the appointment of Patricio Massera as President, in addition to his role on the VIVEbiotech Board of Directors. The appointment marks a significant step in VIVEbiotech's strategy to scale its capabilities, expand globally, and enhance operational quality and excellence following a recent growth investment from Ampersand Capital Partners, a life sciences and healthcare-focused private equity firm. Mr. Massera has over 25 years of leadership experience in the biopharmaceutical CDMO sector. Most recently, he served as CEO of AGC Biologics, where he led the company through global facility expansions and advanced its reputation for quality, innovation, and customer satisfaction. In his prior executive roles, Patricio focused on scaling operations, driving quality and operational excellence, and building world-class teams. 'I am honored to join VIVEbiotech at such a pivotal point in its evolution. I firmly believe that VIVE's unique value proposition is redefining the standards by which CDMOs address customer needs and drive meaningful advancements that improve lives.' said Mr. Massera. 'I look forward to working closely with the Board and the leadership team to enhance operational robustness, expand capabilities, and strengthen the strategic partnerships that define VIVE's commitment to customer success.' Mr. Massera joins VIVEbiotech's leadership team alongside Chairperson Dr. Stefan Beyer—a seasoned CDMO executive and former CEO of Vibalogics—and CEO Jon Alberdi, who has led the company's emergence as a global leader in lentiviral vector manufacturing. 'Patricio brings a unique combination of strategic vision, technical expertise, and operational excellence,' said Dr. Stefan Beyer, Chairperson of VIVEbiotech. 'He has consistently demonstrated a strong ability to scale organizations while upholding excellence in quality and customer service. The Board is confident in his ability to help lead VIVEbiotech into its next phase of growth. We are delighted to welcome him and look forward to working closely together.' Jon Alberdi, CEO, VIVEbiotech added, 'Patricio's deep industry knowledge and leadership skills are a perfect fit for our ambitious goals. I look forward to working together to deliver exceptional value to our clients and to further strengthen our position as a leading CDMO.' VIVEbiotech is one of the few CDMOs globally with deep expertise in both ex vivo and in vivo lentiviral vector development and manufacturing. Its fully integrated service offering supports therapies across a range of indications, including oncology (CAR-T, NK), autoimmune diseases, and vaccines. VIVE serves established global pharmaceutical leaders as well as emerging, innovative start-ups, with a customer base spanning Europe, the U.S., and Australia. About VIVEbiotechVIVEbiotech is a Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral vectors for gene and cell therapy. Founded in 2015, VIVEbiotech operates under EMA and FDA standards, serving over 40 biotech companies globally. The company focuses on scalable, high-yield manufacturing processes and cutting-edge technologies. With expertise in both ex vivo and in vivo applications, VIVEbiotech supports the development and commercialization of therapies for cancers and rare diseases. For more information about VIVEbiotech, please visit About Ampersand Capital PartnersAmpersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit or follow us on LinkedIn. Attachments VIVEbiotech Patricio Massera CONTACT: Naiara Tejados, PhD VIVEbiotech T +34 943 308 568 – Ext. 244 ntejados@ in to access your portfolio
Yahoo
22-05-2025
- Business
- Yahoo
Ampersand Capital Partners Ranked #1 Globally for Growth Capital Private Equity Performance for the Third Consecutive Year by HEC Paris–Dow Jones
HEC Paris Boston, MA, May 22, 2025 (GLOBE NEWSWIRE) -- Ampersand Capital Partners has ranked #1 for growth capital private equity performance globally by HEC Paris–Dow Jones, marking the third consecutive year the firm has earned this prestigious distinction. 'This achievement reflects the dedication and depth of our investment team, our disciplined focus in the healthcare sector, and the outstanding efforts of our portfolio company management teams,' said Herb Hooper, Managing Partner at Ampersand Capital Partners. 'We are honored to be recognized by such a prestigious institution as HEC Paris-Dow Jones.' The annual ranking, led by Professor Oliver Gottschalg of HEC Paris in collaboration with Dow Jones, analyzed the performance of 278 growth capital firms and 505 funds raised between 2011 and 2020, with an aggregate equity volume of $329B. The report for 2024 notes increased global competition in the growth capital landscape, including the entrance of UK and Japanese firms into the global Top 10 for the first time. Despite this heightened competition, Ampersand maintained its leadership position, underscoring its sustained and consistent performance. Source: The HEC Paris-Dow Jones Growth Capital Performance Ranking of Growth Capital Funds 2024 was issued on May 12, 2025 based on data gathered as of December 2024. HEC Paris analyzed performance data from 278 growth capital firms and the 505 funds they raised between 2011 and 2020 with an aggregate equity volume of $329B. The ranking, conducted by Professor Oliver Gottschalg from HEC Business School in Paris and Dow Jones, evaluated private equity fund performance provided by Preqin and data reported directly to HEC Paris-DowJones. Ampersand did not provide cash or non-cash compensation directly or indirectly in connection with obtaining or using this ranking. Past performance and such ranking are not a guarantee of future results. See the full report and methodology here. About Ampersand Capital Partners Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit or follow us on LinkedIn. Attachment HEC Paris CONTACT: Kathleen Toomey Ampersand Capital Partners kpt@
Yahoo
22-05-2025
- Business
- Yahoo
Ampersand Capital Partners Ranked #1 Globally for Growth Capital Private Equity Performance for the Third Consecutive Year by HEC Paris–Dow Jones
HEC Paris Boston, MA, May 22, 2025 (GLOBE NEWSWIRE) -- Ampersand Capital Partners has ranked #1 for growth capital private equity performance globally by HEC Paris–Dow Jones, marking the third consecutive year the firm has earned this prestigious distinction. 'This achievement reflects the dedication and depth of our investment team, our disciplined focus in the healthcare sector, and the outstanding efforts of our portfolio company management teams,' said Herb Hooper, Managing Partner at Ampersand Capital Partners. 'We are honored to be recognized by such a prestigious institution as HEC Paris-Dow Jones.' The annual ranking, led by Professor Oliver Gottschalg of HEC Paris in collaboration with Dow Jones, analyzed the performance of 278 growth capital firms and 505 funds raised between 2011 and 2020, with an aggregate equity volume of $329B. The report for 2024 notes increased global competition in the growth capital landscape, including the entrance of UK and Japanese firms into the global Top 10 for the first time. Despite this heightened competition, Ampersand maintained its leadership position, underscoring its sustained and consistent performance. Source: The HEC Paris-Dow Jones Growth Capital Performance Ranking of Growth Capital Funds 2024 was issued on May 12, 2025 based on data gathered as of December 2024. HEC Paris analyzed performance data from 278 growth capital firms and the 505 funds they raised between 2011 and 2020 with an aggregate equity volume of $329B. The ranking, conducted by Professor Oliver Gottschalg from HEC Business School in Paris and Dow Jones, evaluated private equity fund performance provided by Preqin and data reported directly to HEC Paris-DowJones. Ampersand did not provide cash or non-cash compensation directly or indirectly in connection with obtaining or using this ranking. Past performance and such ranking are not a guarantee of future results. See the full report and methodology here. About Ampersand Capital Partners Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit or follow us on LinkedIn. Attachment HEC Paris CONTACT: Kathleen Toomey Ampersand Capital Partners kpt@
Yahoo
25-02-2025
- Business
- Yahoo
Julius Clinical Strengthens its European Capabilities by Expanding Operations in Poland
ZEIST, Netherlands, Feb. 25, 2025 /PRNewswire/ -- Julius Clinical, a science-driven global CRO specializing in Neurological, Cardio-Metabolic, Renal and Rare Diseases, is pleased to announce the establishment of Julius Clinical Poland, a new operational hub in Krakow. This expansion reinforces Julius Clinical's position as a global leader in CNS and Cardio-Metabolic research while enhancing its pan-European capabilities in clinical trials. With a strong track record of over 15 clinical trials conducted in Poland during the last years, Julius Clinical recognizes the country's exceptional potential as a key clinical research hub in Europe. Poland offers a highly skilled workforce, a robust healthcare infrastructure, and a proven commitment to clinical research, making it an optimal destination for expanding the company's European footprint. The new affiliate will enable more efficient patient recruitment, improved site selection, and seamless regulatory compliance, ultimately accelerating the development of innovative therapies. Martijn Wallert, CEO of Julius Clinical, said: "Expanding into Poland marks a strategic milestone for Julius Clinical. We are strengthening our presence in Eastern Europe, making Poland a central hub for our regional operations and expanding our ability to support clinical research across neighboring countries." Radek Korba, Country Manager Poland, brings long-standing collaboration experience with Julius Clinical, ensuring a smooth transition for customers and partners. "Poland is a pivotal market in clinical research, and our local presence allows us to drive innovation while maintaining the highest standards of quality and compliance. We are excited to strengthen collaborations with investigators, healthcare institutions, and regulatory bodies to deliver impactful research," said Korba. Julius Clinical's expansion into Poland aligns with its broader strategy of providing world-class, scientifically driven clinical research services globally. With this move, the company reinforces its commitment to accelerating medical breakthroughs through cutting-edge trial designs, access to diverse patient populations, and deep scientific expertise. Julius Clinical is supported by Ampersand Capital Partners, a leading private equity firm with deep expertise in the life sciences and healthcare sectors. About Julius Clinical Founded in 2008 and headquartered in Zeist, The Netherlands, Julius Clinical is a leading CRO specializing in CNS, Cardio-Metabolic, Renal, and Rare Diseases. With over 380 clinical trials and 220,000+ subjects across 39 countries, Julius Clinical combines scientific leadership, operational excellence, and a global network of research sites to deliver tailored solutions for pharmaceutical, biotechnology, and academic partners. For more information, visit or follow us on LinkedIn. About Ampersand Capital Partners Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, The Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit or follow us on LinkedIn. For more information on Julius Clinical services: Email: businessdevelopment@ For more information on this press release, please contact: Toni KovandjievaMarketing Manager, Julius ClinicalEmail: View original content to download multimedia: SOURCE Julius Clinical Research
